SI3151832T1 - Postopki za povečanje tonične inhibicije in zdravljenje sekundarne nespečnosti - Google Patents

Postopki za povečanje tonične inhibicije in zdravljenje sekundarne nespečnosti

Info

Publication number
SI3151832T1
SI3151832T1 SI201531616T SI201531616T SI3151832T1 SI 3151832 T1 SI3151832 T1 SI 3151832T1 SI 201531616 T SI201531616 T SI 201531616T SI 201531616 T SI201531616 T SI 201531616T SI 3151832 T1 SI3151832 T1 SI 3151832T1
Authority
SI
Slovenia
Prior art keywords
methods
treating secondary
tonic inhibition
secondary insomnia
increasing tonic
Prior art date
Application number
SI201531616T
Other languages
English (en)
Slovenian (sl)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics, Inc. filed Critical Ovid Therapeutics, Inc.
Publication of SI3151832T1 publication Critical patent/SI3151832T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
SI201531616T 2014-06-06 2015-06-03 Postopki za povečanje tonične inhibicije in zdravljenje sekundarne nespečnosti SI3151832T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462008939P 2014-06-06 2014-06-06
EP15803364.7A EP3151832B1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia
PCT/US2015/034018 WO2015187851A1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia

Publications (1)

Publication Number Publication Date
SI3151832T1 true SI3151832T1 (sl) 2021-08-31

Family

ID=54767324

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201531620T SI3372229T1 (sl) 2014-06-06 2015-06-03 Postopki za povečanje tonične inhibicije in zdravljenje angelman sindroma
SI201531616T SI3151832T1 (sl) 2014-06-06 2015-06-03 Postopki za povečanje tonične inhibicije in zdravljenje sekundarne nespečnosti

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201531620T SI3372229T1 (sl) 2014-06-06 2015-06-03 Postopki za povečanje tonične inhibicije in zdravljenje angelman sindroma

Country Status (20)

Country Link
US (11) US20150352085A1 (enExample)
EP (3) EP3372229B1 (enExample)
JP (4) JP2017516868A (enExample)
AR (1) AR100772A1 (enExample)
AU (4) AU2015269667B2 (enExample)
CA (1) CA2950845C (enExample)
CY (2) CY1124366T1 (enExample)
DK (2) DK3151832T3 (enExample)
ES (2) ES2876350T3 (enExample)
HR (2) HRP20210901T1 (enExample)
HU (2) HUE055400T2 (enExample)
IL (2) IL249287B (enExample)
LT (2) LT3151832T (enExample)
MX (2) MX380868B (enExample)
PL (2) PL3372229T3 (enExample)
PT (2) PT3372229T (enExample)
RS (2) RS62006B1 (enExample)
SI (2) SI3372229T1 (enExample)
SM (2) SMT202100340T1 (enExample)
WO (1) WO2015187851A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3372229T3 (pl) 2014-06-06 2021-10-04 Ovid Therapeutics, Inc. Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana
US10080898B2 (en) * 2015-05-29 2018-09-25 Medtronic, Inc. Simultaneous physiological sensing and stimulation with saturation detection
US10434308B2 (en) 2015-05-29 2019-10-08 Medtronic, Inc. Impedance matching and electrode conditioning in patient interface systems
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
MX391708B (es) 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
WO2018017639A1 (en) * 2016-07-19 2018-01-25 Georgia State University Research Foundation Methods for treating rett syndrome
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
AU2017363598A1 (en) * 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
KR20200047557A (ko) 2017-08-04 2020-05-07 오비드 테라퓨틱스 인크. 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용
US11181384B2 (en) * 2018-07-23 2021-11-23 Waymo Llc Verifying map data using challenge questions
KR20210062662A (ko) 2018-09-20 2021-05-31 오비드 테라퓨틱스 인크. 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용
CN113395962A (zh) * 2018-11-21 2021-09-14 Certego治疗公司 加波沙朵用于降低自杀风险和快速缓解抑郁症
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
US20210015760A1 (en) * 2019-07-15 2021-01-21 Ovid Therapeutics Inc. Pharmaceutical formulations containing gaboxadol for therapeutic treatment
AU2020405060A1 (en) 2019-12-18 2022-06-09 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
AU2021275863A1 (en) 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
JP7600661B2 (ja) * 2020-12-11 2024-12-17 ａｒｔｉｅｎｃｅ株式会社 貼付剤
US20240285562A1 (en) * 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
MXPA06011325A (es) 2004-04-02 2006-12-15 Lundbeck & Co As H Tratamiento de la funcion respiratoria alterada con gaboxadol.
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
WO2009064928A1 (en) 2007-11-13 2009-05-22 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
CA2732636A1 (en) * 2008-09-01 2009-05-07 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of pat1 or oat
PL3372229T3 (pl) 2014-06-06 2021-10-04 Ovid Therapeutics, Inc. Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana
MX391708B (es) * 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Also Published As

Publication number Publication date
ES2876350T3 (es) 2021-11-12
AU2020217342A1 (en) 2020-08-27
US20230051859A1 (en) 2023-02-16
US9339495B2 (en) 2016-05-17
HRP20210901T1 (hr) 2021-09-17
IL268960A (en) 2019-10-31
HRP20210902T1 (hr) 2021-09-17
AU2024202604A1 (en) 2024-05-09
US20180015076A1 (en) 2018-01-18
JP2017516868A (ja) 2017-06-22
US20160228418A1 (en) 2016-08-11
US9801864B2 (en) 2017-10-31
AU2020217342B2 (en) 2021-10-07
US20150352085A1 (en) 2015-12-10
IL249287B (en) 2021-03-25
CY1124366T1 (el) 2022-07-22
JP2021178836A (ja) 2021-11-18
US20170273956A1 (en) 2017-09-28
US20160038469A1 (en) 2016-02-11
AR100772A1 (es) 2016-11-02
MX2016016136A (es) 2017-07-05
CA2950845A1 (en) 2015-12-10
SMT202100340T1 (it) 2021-07-12
CY1124368T1 (el) 2022-07-22
CA2950845C (en) 2023-04-25
SI3372229T1 (sl) 2021-09-30
AU2015269667A1 (en) 2016-12-22
US11278529B2 (en) 2022-03-22
PL3151832T3 (pl) 2021-10-25
US9744159B2 (en) 2017-08-29
LT3372229T (lt) 2021-07-12
DK3372229T3 (da) 2021-06-14
DK3151832T3 (da) 2021-06-14
US20220016091A1 (en) 2022-01-20
EP3151832A1 (en) 2017-04-12
US20250025448A1 (en) 2025-01-23
JP2023123442A (ja) 2023-09-05
AU2015269667B2 (en) 2020-07-30
US20180303805A1 (en) 2018-10-25
AU2022200085A1 (en) 2022-02-03
US20170071917A1 (en) 2017-03-16
HUE055400T2 (hu) 2021-11-29
PL3372229T3 (pl) 2021-10-04
MX380868B (es) 2025-03-12
RS62007B1 (sr) 2021-07-30
EP3372229A1 (en) 2018-09-12
JP2020063264A (ja) 2020-04-23
US20170087133A1 (en) 2017-03-30
EP3795156A1 (en) 2021-03-24
RS62006B1 (sr) 2021-07-30
LT3151832T (lt) 2021-07-12
IL249287A0 (en) 2017-02-28
HUE055155T2 (hu) 2021-11-29
EP3151832A4 (en) 2018-01-17
IL268960B (en) 2021-05-31
EP3151832B1 (en) 2021-03-24
SMT202100343T1 (it) 2021-07-12
MX391502B (es) 2025-03-21
PT3372229T (pt) 2021-06-17
EP3372229B1 (en) 2021-03-24
ES2875742T3 (es) 2021-11-11
WO2015187851A1 (en) 2015-12-10
US9446028B2 (en) 2016-09-20
PT3151832T (pt) 2021-06-15
MX2020012404A (es) 2022-04-11

Similar Documents

Publication Publication Date Title
IL249287B (en) Methods for increasing tonic inhibition and treating secondary insomnia
ZA202006746B (en) Methods of treatment
IL283799B (en) Compounds and methods for the treatment of RNA-mediated diseases
GB2595063B (en) Modified cells and methods of therapy
IL267291B (en) Actonucleotidase inhibitors and methods of using them
IL249658A0 (en) Methods of treating cancer using tigit inhibitors and anticancer agents
IL259801A (en) ezh2 inhibitors and methods of using them
PL3548033T3 (pl) Związki i sposoby ich stosowania
IL251759A0 (en) Preparations and methods for treating insomnia
PT3233071T (pt) Método de tratamento ou prevenção de doenças mediadas por ras
LT3661510T (lt) Elgesio pakitimų gydymo būdai
IL256181A (en) Means and methods for treatment of b-cell malignancies
GB201511799D0 (en) Composition and methods of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201621737D0 (en) Compositions and methods of treatment
GB201605127D0 (en) Composition and methods of treatment
PT3268376T (pt) Inibidores de enolase e métodos de tratamento com os mesmos
PT3661510T (pt) Métodos de tratamento de alterações do comportamento
GB201702189D0 (en) Theory of time and energy
GB201418640D0 (en) Agents and methods for treatment of cancer
GB201510576D0 (en) Implants and methods of forming thereof
GB201421511D0 (en) Methods of screening and treatment
AP2016009662A0 (en) Combination of taurine and racemethionine for treatment of liver diseases